URGENT UPDATE: The US Food and Drug Administration has just approved a groundbreaking pill version of Wegovy, providing a more affordable and convenient option for weight management. This new oral medication, developed by Novo Nordisk, is set to hit pharmacies in early January 2024, priced at just $149 per month, significantly lower than the injectable version, which costs approximately $1,350 monthly.
The FDA’s decision marks a pivotal moment in weight-loss treatments, as Wegovy becomes the first pill-based GLP-1 drug approved specifically for weight management. The once-daily pill contains the same active ingredient, semaglutide, as the injection, but allows patients to avoid needles entirely.
In a late-stage clinical trial involving over 300 patients, participants taking the Wegovy pill lost an average of 16.6% of their body weight over approximately 64 weeks. This weight loss is comparable to that of the injectable version, offering a promising option for those struggling with obesity or overweight conditions. The pill is also approved to help reduce the risk of serious cardiovascular events, such as heart attacks or strokes, in certain patients.
Mike Doustdar, CEO of Novo Nordisk, stated,
“With today’s approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection.”
The rising demand for GLP-1 weight-loss drugs has been notable, with a recent survey from health policy research group KFF indicating that 12% of adult Americans are currently using such medications, a significant increase from previous years. However, the high cost remains a barrier for many, as about half of the users reported difficulties in affording these treatments even with insurance.
As Novo Nordisk prepares for the launch, further details regarding coverage and savings options are expected to be announced closer to the release date. The introduction of the Wegovy pill could revolutionize the weight-loss landscape, making effective treatment more accessible to millions.
Stay tuned for more updates on this developing story as the launch date approaches.
